C0358 Understanding recurrent thrombosis of antiphospholipid syndrome

Harberth Fernandez, Nuria Bermejo Vega, Carolina Martin Aguilera, Fernando Carnicero, Fatima Ibañez Espacio, Maria Jose Arcos Carmona, Maria Elena Bañas, Carmen Cabrera Silva, Julio Prieto, Maria Jose Garcia Blanco, Marisa Martin Mateos, Juan M. Bergua Burgues
  • Thrombosis Research, October 2012, Elsevier
  • DOI: 10.1016/j.thromres.2012.08.163

What is it about?

The antiphospholipid syndrome (APS) is diagnosed in patients with recurrent thromboembolic events and/or pregnancy loss in the presence of clinical or persistent laboratory evidence for antiphospholipid antibodies. Diagnostic tests for the detection of antiphospholipid antibodies include laboratory assays that detect anticardiolipin antibodies, lupus anticoagulants, and anti-β(2) -glycoprotein I antibodies. Antithrombotic drugs are the therapeutic elections for patients with antiphospholipid syndrome (APS) whereas choosing the intensity of anticoagulation and the duration of treatment has been a recurrent matter of debate.

Read Publication


The following have contributed to this page: Dr Nuria Bermejo